Pustular psoriasis treated with IL-17a antibody secukinumab

Руднева, Н. С.; Natarova, E. V.; Круглова, Л. С.

doi:10.33667/2078-5631-2022-27-30-36

Medicinskij alfavit

2022

DOI: 10.33667/2078-5631-2022-27-30-36

|View full text |Cite

Pustular psoriasis treated with IL-17a antibody secukinumab

Н. С. Руднева

E. V. Natarova

Л. С. Круглова

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Experience of using the interleukin-17A inhibitor secukinumab in the treatment of psoriasis and psoriatic arthritis

Molochkova,

Petrova,

Molochkov

et al. 2023

Russian Journal of Skin and Venereal Diseases

View full text Add to dashboard Cite

Psoriasis is a chronic immune-inflammatory skin disease, which in 25–30% of cases occurs in combination with damage of the musculoskeletal system ― psoriatic arthritis. Nowadays, the leading role in the pathogenesis of psoriasis and psoriatic arthritis is assigned to the activation of the IL-23/IL-17 axis-key cytokines involved in the activation pathway of the effector activity of Th17 lymphocytes. The activity of proinflammatory cytokines secreted by Th17 cells in psoriasis and psoriatic arthritis is also confirmed by the high efficiency of targeted therapy aimed specifically at this pathway. One of the modern genetically engineered biological drugs blocking IL-17 which is used worldwide in the treatment of psoriasis and psoriatic arthritis is secukinumab, a recombinant, fully human monoclonal antibody of high affinity directed against IL-17A. The article presents data from own 52-week follow-up of secukinumab use in 40 patients with severe and moderate-severe psoriasis which was combined with psoriatic arthritis in 67.5% of cases and demonstrates high efficacy, survival and satisfactory tolerability of this therapy.

show abstract

Experience of using the interleukin-17A inhibitor secukinumab in the treatment of psoriasis and psoriatic arthritis

Molochkova,

Petrova,

Molochkov

et al. 2023

Russian Journal of Skin and Venereal Diseases

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Pustular psoriasis treated with IL-17a antibody secukinumab

Cited by 1 publication

References 12 publications

Experience of using the interleukin-17A inhibitor secukinumab in the treatment of psoriasis and psoriatic arthritis

Experience of using the interleukin-17A inhibitor secukinumab in the treatment of psoriasis and psoriatic arthritis

Contact Info

Product

Resources

About